Title:
TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
Document Type and Number:
WIPO Patent Application WO/2016/146812
Kind Code:
A3
Abstract:
The present invention refers to lixisenatide for use in the reduction of progression of urinary albumin excretion in a type 2 diabetes mellitus patient.
Inventors:
BELDER RENE (US)
JOHNSTON PETER (US)
LAWSON FRANCESCA (US)
PING LIN (US)
WEI XIAODAN (US)
JOHNSTON PETER (US)
LAWSON FRANCESCA (US)
PING LIN (US)
WEI XIAODAN (US)
Application Number:
PCT/EP2016/055954
Publication Date:
November 03, 2016
Filing Date:
March 18, 2016
Export Citation:
Assignee:
SANOFI AVENTIS DEUTSCHLAND (DE)
International Classes:
A61K38/26; A61P3/10; A61P5/50; A61P9/10; A61P13/12
Domestic Patent References:
| WO2012156296A1 | 2012-11-22 | |||
| WO2012156299A1 | 2012-11-22 | |||
| WO2013060850A1 | 2013-05-02 | |||
| WO2012028172A1 | 2012-03-08 |
Other References:
GAME F: "Novel hypoglycaemic agents: Considerations in patients with chronic kidney disease", NEPHRON - CLINICAL PRACTICE 2014 S. KARGER AG CHE, vol. 126, no. 1, 2014, pages 14 - 18, XP002757892, ISSN: 1660-2110
GIORDA CARLO B ET AL: "Pharmacokinetics, safety, and efficacy of DPP-4 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus and renal or hepatic impairment. A systematic review of the literature.", ENDOCRINE AUG 2014, vol. 46, no. 3, August 2014 (2014-08-01), pages 406 - 419, XP002757893, ISSN: 1559-0100
HASSLACHER C ET AL: "Diabetic kidney disease", EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY AND DIABETES JULY 2014 GEORG THIEME VERLAG DEU, vol. 122, no. 7, July 2014 (2014-07-01), pages 391 - 394, XP009190099, ISSN: 0947-7349
PAMELA KATZ ET AL: "The clinical burden of type 2 diabetes in patients with acute coronary syndromes: Prognosis and implications for short- and long-term management", DIABETES & VASCULAR DISEASE RESEARCH, November 2014 (2014-11-01), Sage UK: London, England, pages 395 - 409, XP055295749, Retrieved from the Internet [retrieved on 20160816]
BENTLEY-LEWIS RHONDA ET AL: "Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo", AMERICAN HEART JOURNAL, MOSBY- YEAR BOOK INC, US, vol. 169, no. 5, 12 February 2015 (2015-02-12), pages 631 - 638, XP029574006, ISSN: 0002-8703, DOI: 10.1016/J.AHJ.2015.02.002
DAVID AGUILAR: "Heart failure and diabetes: Time to pay attention", AMERICAN HEART JOURNAL, vol. 162, no. 5, November 2011 (2011-11-01), pages 795 - 797, XP055127419, ISSN: 0002-8703, DOI: 10.1016/j.ahj.2011.08.016
PETERSEN ANDREAS B ET AL: "Clinical potential of lixisenatide once daily treatment for type 2 diabetes mellitus.", DIABETES, METABOLIC SYNDROME AND OBESITY : TARGETS AND THERAPY 2013, vol. 6, 2013, pages 217 - 231, XP002760843, ISSN: 1178-7007
PAULUS WOHLFART ET AL: "Cardioprotective effects of lixisenatide in rat myocardial ischemia-reperfusion injury studies", JOURNAL OF TRANSLATIONAL MEDICINE, BIOMED CENTRAL, LONDON, GB, vol. 11, no. 1, 28 March 2013 (2013-03-28), pages 84, XP021145575, ISSN: 1479-5876, DOI: 10.1186/1479-5876-11-84
JOHN R PETRIE: "The cardiovascular safety of incretin-based therapies: a review of the evidence", CARDIOVASCULAR DIABETOLOGY, BIOMED CENTRAL, LONDON, GB, vol. 12, no. 1, 6 September 2013 (2013-09-06), pages 130, XP021159743, ISSN: 1475-2840, DOI: 10.1186/1475-2840-12-130
RUETTEN H ET AL: "Protective effects of the GLP-1 receptor agonist lixisenatide on ischaemia-reperfusion-induced myocardial infarction in an isolated rat heart model", DIABETOLOGIA, SPRINGER, BERLIN, DE, vol. 54, no. Suppl.1, September 2011 (2011-09-01), pages S329, XP009163469, ISSN: 0012-186X
HUEBSCHLE T ET AL: "Anti-atherosclerotic activity of lixisenatide in ApoE knockout mice", DIABETOLOGIA, vol. 55, no. Suppl. 1, October 2012 (2012-10-01), & 48TH ANNUAL MEETING OF THE EUROPEAN-ASSOCIATION-FOR-THE-STUDY-OF-DIABETES; BERLIN, GERMANY; OCTOBER 01 -05, 2012, pages S334, XP009191395
GIORDA CARLO B ET AL: "Pharmacokinetics, safety, and efficacy of DPP-4 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus and renal or hepatic impairment. A systematic review of the literature.", ENDOCRINE AUG 2014, vol. 46, no. 3, August 2014 (2014-08-01), pages 406 - 419, XP002757893, ISSN: 1559-0100
HASSLACHER C ET AL: "Diabetic kidney disease", EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY AND DIABETES JULY 2014 GEORG THIEME VERLAG DEU, vol. 122, no. 7, July 2014 (2014-07-01), pages 391 - 394, XP009190099, ISSN: 0947-7349
PAMELA KATZ ET AL: "The clinical burden of type 2 diabetes in patients with acute coronary syndromes: Prognosis and implications for short- and long-term management", DIABETES & VASCULAR DISEASE RESEARCH, November 2014 (2014-11-01), Sage UK: London, England, pages 395 - 409, XP055295749, Retrieved from the Internet
BENTLEY-LEWIS RHONDA ET AL: "Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo", AMERICAN HEART JOURNAL, MOSBY- YEAR BOOK INC, US, vol. 169, no. 5, 12 February 2015 (2015-02-12), pages 631 - 638, XP029574006, ISSN: 0002-8703, DOI: 10.1016/J.AHJ.2015.02.002
DAVID AGUILAR: "Heart failure and diabetes: Time to pay attention", AMERICAN HEART JOURNAL, vol. 162, no. 5, November 2011 (2011-11-01), pages 795 - 797, XP055127419, ISSN: 0002-8703, DOI: 10.1016/j.ahj.2011.08.016
PETERSEN ANDREAS B ET AL: "Clinical potential of lixisenatide once daily treatment for type 2 diabetes mellitus.", DIABETES, METABOLIC SYNDROME AND OBESITY : TARGETS AND THERAPY 2013, vol. 6, 2013, pages 217 - 231, XP002760843, ISSN: 1178-7007
PAULUS WOHLFART ET AL: "Cardioprotective effects of lixisenatide in rat myocardial ischemia-reperfusion injury studies", JOURNAL OF TRANSLATIONAL MEDICINE, BIOMED CENTRAL, LONDON, GB, vol. 11, no. 1, 28 March 2013 (2013-03-28), pages 84, XP021145575, ISSN: 1479-5876, DOI: 10.1186/1479-5876-11-84
JOHN R PETRIE: "The cardiovascular safety of incretin-based therapies: a review of the evidence", CARDIOVASCULAR DIABETOLOGY, BIOMED CENTRAL, LONDON, GB, vol. 12, no. 1, 6 September 2013 (2013-09-06), pages 130, XP021159743, ISSN: 1475-2840, DOI: 10.1186/1475-2840-12-130
RUETTEN H ET AL: "Protective effects of the GLP-1 receptor agonist lixisenatide on ischaemia-reperfusion-induced myocardial infarction in an isolated rat heart model", DIABETOLOGIA, SPRINGER, BERLIN, DE, vol. 54, no. Suppl.1, September 2011 (2011-09-01), pages S329, XP009163469, ISSN: 0012-186X
HUEBSCHLE T ET AL: "Anti-atherosclerotic activity of lixisenatide in ApoE knockout mice", DIABETOLOGIA, vol. 55, no. Suppl. 1, October 2012 (2012-10-01), & 48TH ANNUAL MEETING OF THE EUROPEAN-ASSOCIATION-FOR-THE-STUDY-OF-DIABETES; BERLIN, GERMANY; OCTOBER 01 -05, 2012, pages S334, XP009191395
Attorney, Agent or Firm:
WEICKMANN & WEICKMANN PARTMBB (München, DE)
Download PDF: